ImmunityBio (NASDAQ:IBRX) Shares Climb 10.3% – Still a Buy?

Posted by Brenda Bartman on Oct 27th, 2026

ImmunityBio, Inc. (NASDAQ:IBRX – Get Free Report) shares shot up 10.3% on Tuesday. The stock traded as high as $8.57 and last traded at $8.6150. Approximately 4,103,782 shares traded hands during trading, a decline of 80% from the average session volume of 20,299,053 shares. The stock had previously closed at $7.81.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on the stock. Jefferies Financial Group boosted their price objective on shares of ImmunityBio from $12.00 to $14.00 and gave the company a “buy” rating in a research report on Wednesday, October 14th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of ImmunityBio in a research report on Tuesday, October 6th. Piper Sandler reaffirmed an “overweight” rating and set a $16.00 price target on shares of ImmunityBio in a research report on Wednesday, October 14th. Finally, HC Wainwright reiterated a “buy” rating and issued a $15.00 target price on shares of ImmunityBio in a research report on Thursday, October 15th. Six analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $16.00.

View Our Latest Stock Report on ImmunityBio

ImmunityBio Trading Up 9.2%

The company has a fifty day moving average of $8.65 and a 200-day moving average of $7.73. The company has a market capitalization of $9.04 billion, a price-to-earnings ratio of -8.79 and a beta of 0.02.

ImmunityBio (NASDAQ:IBRX – Get Free Report) last issued its quarterly earnings results on Tuesday, August 4th. The company reported ($0.22) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.14). The firm had revenue of $51.24 million during the quarter, compared to analysts’ expectations of $49.70 million. As a group, equities research analysts expect that ImmunityBio, Inc. will post -0.30 EPS for the current year.

Insiders Place Their Bets

In related news, Director Barry Simon sold 25,000 shares of ImmunityBio stock in a transaction that occurred on Monday, October 5th. The shares were sold at an average price of $10.75, for a total value of $268,750.00. Following the completion of the sale, the director owned 2,777,788 shares in the company, valued at approximately $29,861,221. This trade represents a 0.89% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Cheryl Cohen sold 81,056 shares of the stock in a transaction dated Friday, October 2nd. The stock was sold at an average price of $10.50, for a total value of $851,088.00. Following the transaction, the director directly owned 100,309 shares in the company, valued at approximately $1,053,244.50. The trade was a 44.69% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 66.10% of the company’s stock.

Institutional Trading of ImmunityBio

Hedge funds and other institutional investors have recently made changes to their positions in the company. BlackRock Inc. boosted its holdings in shares of ImmunityBio by 29.4% in the second quarter. BlackRock Inc. now owns 34,083,262 shares of the company’s stock valued at $298,399,000 after acquiring an additional 7,736,819 shares during the period. State Street Corp boosted its stake in shares of ImmunityBio by 20.8% during the second quarter. State Street Corp now owns 21,398,438 shares of the company’s stock worth $187,343,000 after buying an additional 3,690,335 shares during the period. Bank of America Corp DE boosted its stake in shares of ImmunityBio by 2.7% during the first quarter. Bank of America Corp DE now owns 2,447,843 shares of the company’s stock worth $18,775,000 after buying an additional 65,340 shares during the period. SEB Asset Management AB purchased a new position in shares of ImmunityBio during the first quarter worth about $18,770,000. Finally, Private Advisor Group LLC grew its holdings in shares of ImmunityBio by 923.5% during the first quarter. Private Advisor Group LLC now owns 1,648,556 shares of the company’s stock worth $12,644,000 after buying an additional 1,487,482 shares during the last quarter. Institutional investors and hedge funds own 8.58% of the company’s stock.

About ImmunityBio

(Get Free Report)

ImmunityBio, Inc is a biotechnology company focused on developing and commercializing immunotherapies designed to activate and strengthen the body’s immune response against cancer and infectious diseases. The company’s approach combines immune-system modulators, cellular therapies, vaccines and other technologies intended to address multiple stages of the disease-treatment process.

Its lead product, Anktiva (nogapendekin alfa inbakicept-pmln, also known as N-803), is an interleukin-15 receptor agonist designed to stimulate natural killer cells and T cells.